THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Angelalign Technology Inc., you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

ANGELALIGN TECHNOLOGY INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6699)

(1) GRANT OF RSUS TO EXECUTIVE DIRECTORS UNDER THE POST-IPO RSU SCHEME; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING

A letter from the Board is set out on pages 3 to 16 of this circular. A notice convening the extraordinary general meeting (the "EGM") of Angelalign Technology Inc. to be held at 6/F, Building No. 7, KIC Business Center, No. 500 Zhengli Road, Yangpu District, Shanghai, PRC on Wednesday, September 30, 2026 at 9:00 a.m. is set out on pages 17 to 18 of this circular. A form of proxy for use at the EGM is also enclosed. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.angelalign.com).

Whether or not you are able to attend the EGM, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the EGM (i.e. before 9:00 a.m. on Monday, September 28, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude shareholders from attending and voting in person at the EGM (or any adjournment thereof) if they so wish. In such event, the form of proxy shall be deemed to be revoked.

September 11, 2026

CONTENTS

Page

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

"Articles of Association"	the articles of association of the Company, as amended from time to time
"associate(s)"	has the meaning as defined under the Listing Rules
"Board"	the board of Directors
"Company"	Angelalign Technology Inc. (時代天使科技有限公司), an exempted company incorporated under the laws of Cayman Islands with limited liability on November 29, 2018, the shares of which are listed on the Main Board of the Stock Exchange
"connected person(s)"	has the meaning as defined under the Listing Rules
"core connected person(s)"	has the meaning as defined under the Listing Rules
"Director(s)"	director(s) of the Company
"Extraordinary General Meeting" or "EGM"	the extraordinary general meeting of the Company to be held on or around Wednesday, September 30, 2026, which will be further notified by the Company in due course
"Grantees"	the individual(s) who are granted RSUs pursuant to the Post-IPO RSU Scheme
"Group"	the Company and its subsidiaries
"HK$" and "cents"	Hong Kong dollars and cents, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Independent Shareholders"	shareholders who are not required to abstain from voting in favour of the resolutions proposed at the EGM according to the Listing Rules, referring to Shareholders other than Mr. Feng, Mr. Hu and Mr. Huang, their associates and all core connected persons of the Company

"Latest Practicable Date"	September 10, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Mr. Feng"	Mr. FENG Dai, being an executive Director, chairman of the Board and controlling shareholder of the Company
"Mr. Hu"	Mr. HU Jiezhang, being an executive Director, Chief Executive Officer and Chief Technology Officer of the Company
"Mr. Huang"	Mr. HUANG Kun, being an executive Director and the president of global business (ex-Chinese mainland) of the Company
"Post-IPO RSU Scheme"	the post-IPO RSU scheme of the Company as adopted on May 20, 2021 and as amended from time to time
"Remuneration Committee"	the remuneration committee of the Board
"RSU(s)"	the restricted share unit(s) that may be granted under the Post-IPO RSU Scheme
"Share(s)"	ordinary share(s) in the share capital of the Company of US$0.0001 each
"Shareholder(s)"	holder(s) of the Shares of the Company
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"%"	per cent.

ANGELALIGN TECHNOLOGY INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6699)

Executive Directors:
Mr. FENG Dai (*Chairman*)
Mr. HU Jiezhang (*Chief Executive Officer*)
Mr. HUANG Kun
Ms. DONG Li

Independent non-executive Directors:
Mr. HAN Xiaojing
Mr. SHI Zi
Mr. ZHOU Hao

Registered Office:
Maples Corporate Services Limited
PO Box 309
Ugland House
Grand Cayman KY1-1104
Cayman Islands

Corporate headquarters:
6/F-7/F, Building No. 7
KIC Business Center
No. 500 Zhengli Road
Yangpu District
Shanghai, PRC

Principal place of business in Hong Kong:
Room 1920, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong

September 11, 2026

To the Shareholders

Dear Sir or Madam,

(1) GRANT OF RSUS TO EXECUTIVE DIRECTORS UNDER THE POST-IPO RSU SCHEME; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING

INTRODUCTION

Reference is made to the announcement of the Company dated September 11, 2026 in relation to, among other things, the conditional grants of RSUs to Mr. Feng, Mr. Hu and Mr. Huang (the "**Selected Director Grantees**"). The purpose of this circular is to provide you with information in respect of the resolutions to be proposed to seek approval of the Shareholders in respect of the one-time, three-year retrospective grants of RSUs to the Selected Director Grantees for extraordinary performance already delivered (the "**Three-year RSU Grants**").

The Three-year RSU Grants form part of a broader grant of 1,563,929 RSUs to 16 members of the management team, and are intended to recognize the Selected Director Grantees' leadership and invaluable contributions in strengthening the Group's Chinese mainland business and leveraging its capabilities and resources to build its global business from scratch into one that, after three years, contributed more than half of the Group's total clear aligner case volume from markets outside Chinese mainland and achieved profitability in the first half of 2026. For details about the grant of RSUs to other members of the management team, please refer to the Company's announcement dated September 11, 2026.

The Three-year RSU Grants are a one-time, three-year retrospective award to recognize historical contributions, determined only after the Group had achieved and exceeded key milestones contemplated under its initial three-year globalization plan. None of the Selected Director Grantees has previously received any equity incentive award from the Company.

At the commencement of the plan, the Group was at an early stage of its globalization journey. The Board, the Remuneration Committee and the Selected Director Grantees themselves considered it appropriate for the Selected Director Grantees to focus on the implementation of the globalization strategy and the creation of long-term shareholder value, while prioritizing equity incentives for other employees involved in the plan. They considered that deferring their own equity awards until the key milestone targets had been achieved placed value creation ahead of their own equity compensation. The Board and the Remuneration Committee consider that this approach demonstrated both the alignment of the Selected Director Grantees' interests with those of the Shareholders and their ownership mindset and long-term commitment to the Group's globalization strategy.

The Board considers the speed and scale of the Group's transformation in globalization particularly noteworthy. This was not simply geographic expansion; it required the Group to become a fundamentally more global organization in its people, capabilities, culture and operating model. Building a global business from a predominantly domestic operation requires earning the trust of new customers, adapting to different clinical practices and market environments, attracting and empowering international talent, and navigating complex regulatory and operational requirements across multiple jurisdictions.

These achievements were made possible by the collective efforts of the Group's employees and the trust and partnership of its customers around the world. Within this collective effort, the Board considers the respective roles and contributions of each of the Selected Director Grantees during this period in the following areas:

(i) As Chairman of the Board, Mr. Feng has provided overall strategic leadership and stewardship for the Group through its transformation into an increasingly global company. Having served as a non-executive Director prior to his re-designation as an executive Director in April 2026, Mr. Feng has drawn on his extensive industry experience, investment and professional network and long-standing knowledge of the Group to exercise long-term judgment in major strategic, business development and capital allocation decisions, while providing the Board-level support and resources necessary to pursue globalization through its investment and development phase. He has played an important role in major strategic partnerships, investments and other business development initiatives, and provided leadership in navigating complex regulatory, legal and compliance matters and strengthening corporate governance and risk management as the Group expanded across jurisdictions. Mr. Feng has also helped establish clear priorities and operating principles centered on customers, clinical excellence, long-term value creation and ownership, while fostering an open and collaborative culture. As Chairman, he has supported the development of the Group's leadership team and employee incentive framework, reinforcing alignment around the Group's long-term objectives.

(ii) As an executive Director, Chief Executive Officer and Chief Technology Officer, Mr. Hu has provided company-wide leadership in translating the Group's strategy into execution and operating results. He has led the Group's strategic planning and day-to-day management, including strengthening its Chinese mainland business and achieving continued growth and market share gains amid strong competition. As the Group globalized, he has driven collaboration between headquarters and international regions and the sharing of technology, product innovation, clinical expertise and operating capabilities across markets, enabling capabilities developed across the Group to support different markets and creating increasingly two-way learning between Chinese mainland and international operations. Mr. Hu has also led continued investment and innovation in technology, products and clinical capabilities, while strengthening and globalizing the Group's treatment planning, manufacturing and supply chain capabilities. During the Group's CEO and management transition, he played an important role in maintaining leadership continuity, organizational stability and execution momentum while supporting the Group's continued transformation.

(iii) As a long-serving Director and, subsequently, the President of Global Business (ex-Chinese mainland), Mr. Huang has played a leading role in initiating and building the Group's globalization. When the Group remained primarily focused on its home market, he took the lead at the Board level in initiating the globalization effort and building alignment around the transformation. His deep knowledge of the Group, combined with extensive international industry experience, enabled him to chart a practical path for globalization that built on the Group's strengths and addressed international market requirements. He led the development of the globalization roadmap, business and investment plans, including market prioritization, go-to-market strategies, capability requirements and resource allocation, and helped secure support for the required investments. He was instrumental in building strong global and regional leadership teams, empowering them and mobilizing headquarters support for the transformation. He helped bridge cultural and operating-model differences and remove organizational barriers, uniting teams around a common global vision. In addition to leading the international business, he has contributed to maintaining organizational stability through the Group's management transition and to major strategic partnerships, investments and acquisitions supporting the Group's development.

In assessing the appropriate size of the Three-year RSU Grants, the Board and the Remuneration Committee (excluding the Selected Director Grantees) considered, among other factors, the Selected Director Grantees' significant contributions and leadership as described above, as well as the remuneration packages of comparable publicly traded global dental companies. Specifically, the Board and the Remuneration Committee (excluding the Selected Director Grantees) reviewed the 2025 equity-based compensation awarded to directors and senior management of a group of comparable companies with business models and product offerings broadly comparable to those of the Company, including Align Technology, Inc. (Nasdaq: ALGN), Envista Holdings Corporation (NYSE: NVST), Straumann Holding AG (SIX: STMN), Solventum Corporation (NYSE: SOLV), Dentsply Sirona Inc. (Nasdaq: XRAY) and Henry Schein, Inc. (Nasdaq: HSIC). In assessing the comparability of such peers, the Board and the Remuneration Committee considered, among other factors, (i) company size, primarily with reference to market capitalization and revenue scale, noting that the peer companies had market capitalizations ranging from approximately US$2.3 billion to US$20.0 billion and generated annual revenues ranging from approximately US$2.7 billion to US$13.1 billion in 2025; (ii) development stage, taking into account the relative maturity of the peers in product development, commercialization capabilities and international market presence; and (iii) business complexity, considering factors such as the breadth of product portfolios, the diversity of target markets served and the operational complexity associated with managing multiple product categories and end-user groups. Based on the foregoing assessment, the Board and the Remuneration Committee applied an appropriate discount to the equity-based compensation levels observed among such peers after considering their generally larger scale and more mature stage of development relative to our Company, while recognizing the complexity of our business operations, in assessing the reasonableness of the value of equity-based compensation granted to the Selected Director Grantees. The annual compensation package of chief executive officers of the selected comparable companies in 2025 ranged from approximately US$6.2 million to US$20.1 million, of which the annual equity-based incentive awards granted to such chief executive officers ranged from approximately US$1.2 million to US$16.6 million. As the Three-year RSU Grants were intended to recognize contributions over a three-year period, the above compensation and equity incentive levels were used as annualized reference points in assessing the grant value of the Selected Director Grantees. The aggregate value of the total compensation package for each Selected Director Grantee for the past three years ranged from approximately US$3.0 million to US$8.5 million, of which the aggregate value of equity-based compensation represented by the Three-year RSU Grants ranged from approximately US$2.0 million to US$7.1 million. The benchmark of chief executive officer compensation was used primarily in assessing the grant value of Mr. Hu, the Chief Executive Officer of the Company, while appropriate downward adjustments were applied to Mr. Huang and Mr. Feng having regard to their respective roles, responsibilities and contributions.

After determining the value of the Three-year RSU Grants, the number of RSUs to be granted to each of the Selected Director Grantees was calculated by reference to the average price of the Company's Shares without adjustment for any corporate actions including dividend declaration and issuance of new Shares under the Company's share incentive schemes during the first and second quarters of 2026 (HK$74.35 per Share), which served as the conversion price. The Board and the Remuneration Committee (excluding the Selected Director Grantees) considered this price representative of the prevailing trading price immediately prior to the Three-year RSU Grants.

The Three-year RSU Grants principally recognize contributions that have already been delivered and reflected in the Group's operational and financial results. The vesting schedule for each of the Selected Director Grantees reflects the combination of the notional grants assumed to have been made over the past three years, with each vesting in accordance with the same vesting schedule as that applicable to other employee grantees.

THREE-YEAR RSU GRANTS UNDER THE POST-IPO RSU SCHEME

On September 11, 2026, the Board (including the independent non-executive Directors) resolved to grant a total of 1,563,929 RSUs to 16 Grantees under the Post-IPO RSU Scheme, which included the grant of 1,255,803 RSUs to the Selected Director Grantees. The Three-year RSU Grants are conditional upon the approval by the Independent Shareholders at the EGM and subject to acceptance of the Selected Director Grantees.

Details of the Three-year RSU Grants are as follows:

Grant Date: the date of EGM (the "**Grant Date**")

Particulars of the Selected Director Grantees and the Three-year RSU Grants: An aggregate of 1,255,803 RSUs will be granted to the Selected Director Grantees, details of which are as follows:

Name of the Director Grantee	Position(s) held with the Company	Number of RSUs granted	Approximately percentage of shareholding(1)	Vesting schedule of the RSUs granted
Mr. Feng	Executive Director and Chairman of the Board	208,617	0.12%	50% shall vest immediately on the Grant Date; 24% shall vest on July 1, 2027; 17% shall vest on July 1, 2028; and 9% shall vest on July 1, 2029

Mr. Hu	Executive Director, Chief Executive Officer and Chief Technology Officer	743,248	0.43%	51% shall vest immediately on the Grant Date; 24% shall vest on July 1, 2027; 17% shall vest on July 1, 2028; and 8% shall vest on July 1, 2029
Mr. Huang	Executive Director and President of Global Business (ex-Chinese mainland)	303,938	0.18%	57% shall vest immediately on the Grant Date; 23% shall vest on July 1, 2027; 13% shall vest on July 1, 2028; and 7% shall vest on July 1, 2029

(1) The calculation is based on the total number of 171,676,633 Shares in issue as of the Latest Practicable Date, without taking into account any Shares that may be issued under the share award schemes of the Company.

The vesting periods for certain RSUs granted are less than 12 months. Pursuant to the Post-IPO RSU Scheme, the vesting period of certain RSUs granted may, at the discretion of the Board, be shorter where the grants of RSUs have a total vesting period of more than 12 months. As such, it is permissible for the vesting period of certain RSUs granted under the Three-year RSU Grants to be less than 12 months.

The Board and the Remuneration Committee (excluding the Selected Director Grantees) consider such vesting arrangement to be appropriate and aligned with the purpose of the Post-IPO RSU Scheme based on the following considerations:

(a) none of the Selected Director Grantees has received any equity incentive from the Company;

(b) the Three-year RSU Grants are retrospective in nature and are primarily intended to recognize and reward the Selected Director Grantees' significant contributions already delivered over the past three years, particularly their leadership in successfully executing the Group's globalization strategy and achieving substantial overseas business growth; and

(c) the vesting schedule for each of the Selected Director Grantees set out above reflects the combination of the notional grants assumed to have been made over the past three years, with each vesting in accordance with the same vesting schedule as that applicable to other employee grantees.

The underlying Shares for the Three-year RSU Grants are held by the trustee of the Post-IPO RSU Scheme and will be transferred to the Selected Director Grantees upon vesting.

Purchase price of the RSUs granted: Nil

Performance target: **1. Performance underlying the RSUs vesting on the Grant Date**

The Three-year RSU Grants were determined only after the Group had achieved and exceeded the key milestone targets under its initial three-year globalization plan. The performance assessment covered multiple key business and financial dimensions, including total clear aligner case volume, total revenue, and net profit. Under the leadership of the Selected Director Grantees, the Group delivered strong performance throughout the implementation of the three-year plan and exceeded all of the 2025 targets under the plan, with an overall completion rate of over 110% across the assessment metrics in 2025.

The momentum continued into the first half of 2026, with the Group's revenue and net profit increasing by 42.9% and 79.6% year-on-year, respectively. Global markets (ex-Chinese mainland) contributed more than half of the Group's total clear aligner case volume and revenue, and achieved profitability ahead of plan, while the business in Chinese mainland continued to gain market share amid strong competition.

More importantly, the past three years have marked a fundamental transformation. With the Selected Director Grantees providing leadership alongside the broader management team, what began as geographic expansion has evolved into a broader transformation of the Company into an increasingly global organization – across its people, capabilities, culture, and operating model. With deep strengths established in professional-service infrastructure, direct sales networks, local market expertise, and corporate culture, the Company is positioned to sustain and extend its development for the long term.

Given that the Three-year RSU Grants are a one-time retrospective award for performance already delivered, and were determined only after the above milestone targets had been achieved and exceeded, the Board and the Remuneration Committee (excluding the Selected Director Grantees) consider that the achieved performance described above constitutes the performance basis for the RSUs vesting on the Grant Date and that no additional prospective performance targets are necessary for such RSUs.

2. Performance targets for RSUs vesting in future years

The RSUs scheduled to vest in future years remain subject to performance conditions. For each relevant year, the Board will assess the performance of each Selected Director Grantee under the Group's established performance evaluation framework, taking into account both quantitative and qualitative indicators. Quantitative indicators include, among others, clear aligner case volume, financial performance and customer satisfaction, while qualitative indicators include organizational development, brand building, service quality, leadership and execution of strategic initiatives. The assessment will also take into account the macroeconomic environment, the Group's operating and financial performance and the responsibilities undertaken by the relevant Selected Director Grantee during the assessment period.

Based on such assessment, the Board will assign a performance grading to the relevant Selected Director Grantee. The RSUs scheduled to vest in the relevant year will vest only if the prescribed performance grading set out in the relevant grant letter is achieved.

Clawback mechanism: The unvested RSUs granted to the Selected Director Grantees will lapse immediately if the Selected Director Grantees, among others, (i) cease to be eligible persons under the Post-IPO RSU Scheme by reason of death, incapacitation, non-renewal of employment contract upon expiry, voluntary resignation, retirement without post-retirement employment, layoff or discontinuance of relevant business segment or other internal reorganization; or (ii) make any attempt or take any action to sell, transfer, assign, charge, mortgage, encumber, hedge or create any interest in favour of any other person over or in relation to any RSUs or any interests or benefits pursuant to the RSUs.

In addition, the unvested RSUs shall automatically lapse if the Selected Director Grantees (i) are guilty of serious misconduct or are found to have seriously breached the terms of employment or service agreement during their employment or service; (ii) commit an act of bankruptcy or become insolvent or make any arrangement or composition with their creditors generally; (iii) are convicted of any criminal offence involving their integrity or honesty or (if so determined by the Board) on any other ground on which an employer would be entitled to terminate their employment at law or pursuant to any applicable laws or under the Selected Director Grantees' service contracts with any member of the Group; (iv) breach any non-compete and/or non-solicitation obligations or commit other misconduct which seriously damages the interests, image or reputation of the Company; or (v) breach any confidentiality agreement or invention assignment agreement between the Selected Director Grantees and the Company (or any affiliate of the Company) or make any unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom the Selected Director Grantees owe an obligation of nondisclosure as a result of their relationship with the Company.

Financial assistance: There are no arrangements for the Company or any of its subsidiaries to provide any financial assistance to the Selected Director Grantees to facilitate the purchase of Shares for the Three-year RSU Grants under the Post-IPO RSU Scheme.

Voting, dividend, transfer and other rights: Unless otherwise approved by the Board, RSUs shall be personal to the Selected Director Grantees and shall not be assignable and no Selected Director Grantees shall in any way sell, transfer, charge, mortgage, encumber or create any interest in favour of any third party over or in relation to any RSUs, except as otherwise permitted under the Post-IPO RSU Scheme. Furthermore, a Selected Director Grantee may not exercise any voting right in respect of the Shares underlying the RSUs prior to their vesting, nor do they have any rights attached to any Shares underlying the RSUs, including but not limited to any rights to any cash or non-cash income, dividends or distributions (including those arising on liquidation of the Company) and/or the sale proceeds of non-cash and non-scrip distributions from any Shares underlying the RSUs, except as otherwise permitted under the Post-IPO RSU Scheme.

REASONS FOR AND THE BENEFITS OF THE THREE-YEAR RSU GRANTS

Following the formulation of the Group's globalization strategy in 2022 and the subsequent implementation of its initial three-year globalization plan, the Selected Director Grantees, together with other senior management, have provided strong leadership in building the Group's global business from scratch into a substantial and profitable operation after three years, including by establishing localized talent and commercial and clinical capabilities, and building the international professional service, operating and supply chain infrastructure required to support its global expansion.

The Board notes that none of the Selected Director Grantees has ever received any equity incentive award from the Company. The Three-year RSU Grants are a one-time, three-year retrospective award to recognize the Selected Director Grantees' invaluable leadership and contributions for extraordinary performance already delivered. The award was determined only after the Group had achieved and exceeded key milestones contemplated under its initial three-year globalization plan.

As described in the section headed "Introduction" in this circular, the Group achieved significant progress in its global business development and broader strategic transformation in the past three years. The Board believes that the Selected Director Grantees made significant contributions to these achievements and to the creation of long-term value for the Group and its shareholders.

The Board further considers that the Three-year RSU Grants will closely align the interests of the Shareholders, the Company and the Selected Director Grantees by linking the Selected Director Grantees' interests with the long-term sustainable growth of the Group. The RSUs will vest in accordance with the terms thereof and are subject to, among other things, continued service and the operating results of the Group, thereby providing retrospective recognition for extraordinary performance already delivered while also maintaining the alignment of interests between the Selected Director Grantees and the Shareholders as a whole.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

The maximum number of Shares that may be issued under the Post-IPO RSU Scheme shall not exceed 13,671,710 Shares. Assuming that the Three-year RSU Grants were approved at the EGM, after the Three-year RSU Grants, 11,635,649 Shares are available for future grant under the scheme limit of the Post-IPO RSU Scheme. No service provider sublimit has been adopted under the Post-IPO RSU Scheme.

LISTING RULES IMPLICATIONS

Pursuant to Rule 17.04(1) of the Listing Rules, any grant of options or awards to a director, chief executive or substantial shareholder of a listed issuer, or any of their respective associates, under a scheme of the listed issuer must be approved by the independent non-executive directors of the listed issuer (excluding any independent non-executive director who is the grantee of the options or awards).

Pursuant to Rule 17.04(2) of the Listing Rules, if any grant of awards (excluding grant of options) to a director (other than an independent non-executive director) or chief executive of the issuer, or any of their associates would result in the shares issued and to be issued in respect of all awards granted (excluding any awards lapsed in accordance with the terms of the scheme) to such person in the 12-month period up to and including the date of such grant, representing in aggregate over 0.1% of the relevant class of shares in issue (excluding treasury shares) (the "**Director 0.1% Limit**"), such further grant of awards must be approved by shareholders of the listed issuer in general meeting in the manner set out in rule 17.04(4). The grantee, his/her associates and all core connected persons of the Company must abstain from voting in favour at such general meeting.

In addition, pursuant to Rule 17.04(3), if any grant of options or awards to an independent non-executive director or a substantial shareholder of the listed issuer, or any of their respective associates, would result in the shares issued and to be issued in respect of all options and awards granted (excluding any options and awards lapsed in accordance with the terms of the scheme) to such person in the 12-month period up to and including the date of such grant representing in aggregate over 0.1% of the relevant class of shares in issue (excluding treasury shares) (the "**Substantial Shareholder 0.1% Limit**"), such further grant of options or awards must be approved by shareholders of the listed issuer in general meeting in the manner set out in rule 17.04(4). The grantee, his/her associates and all core connected persons of the Company must abstain from voting in favour at such general meeting.

As (a) the total number of RSUs to be granted to each of the Selected Director Grantees exceeds the Director 0.1% Limit, and (b) the total number of RSUs to be granted to Mr. Feng, being a controlling shareholder of the Company, exceeds the Substantial Shareholder 0.1% Limit, the Three-year RSU Grants to the Selected Director Grantees must be subject to approval by the Independent Shareholders at the EGM pursuant to Rule 17.04(2), Rule 17.04(3) and Rule 17.04(4) of the Listing Rules, where each of the Selected Director Grantees, his associates and all core connected persons of the Company shall abstain from voting in favour of the relevant resolutions at the EGM pursuant to the Listing Rules.

Each of the Selected Director Grantees, being an executive Director of the Company, has abstained from voting on the Board resolutions for considering and approving the Three-year RSU Grants to himself. Save for the aforesaid, none of the Directors has a material interest in the Board resolutions approving the Three-year RSU Grants. The Three-year RSU Grants have been approved by the independent non-executive Directors in compliance with Rule 17.04(1) of the Listing Rules.

To the best knowledge, belief and information of the Directors, having made all reasonable enquiries, save for Mr. Feng, Mr. Huang, their respective associates and all core connected persons of the Company (please see the table below for details), who are required to abstain from voting in favour of the relevant resolutions in relation to the Three-year RSU Grants, no other Shareholder has a material interest in the relevant resolution which would be required to abstain from voting on the relevant resolutions at the EGM.

As at the Latest Practicable Date, to the best knowledge of the Directors after making reasonable enquiry, Mr. Feng, Mr. Huang, their respective associates and all core connected persons of the Company held 87,386,360 Shares in aggregate, representing 50.90% of the total issued Shares, and include without limitation the following:

Name	**Identity**	**Number of Shares held**	**Approximate percentage of Interest**(1)
CareCapital Orthotech Limited(2)	Mr. Feng's associate and core connected person of the Company	87,168,400	50.77%
Noble Affluent Limited(3)	Mr. Huang's associate and core connected person of the Company	217,200	0.13%
Ms. DONG Li	Core connected person of the Company	760	0.0004%
Total		**87,386,360**	**50.90%**

(1) The calculation is based on the total number of 171,676,633 Shares in issue as of the Latest Practicable Date, without taking into account any Shares that may be issued under the share award schemes of the Company.

(2) CareCapital Orthotech Limited is wholly-owned by CareCapital EA, Inc., which is in turn owned by CareCapital Dental Holdings Limited and CareCapital Moonstone Holdings Limited, a wholly-owned subsidiary of CareCapital Dental Holdings Limited. CareCapital Dental Holdings Limited is controlled by CareCapital Management Group LLC, which is wholly-owned by Mr. Feng, the ultimate controlling person of CareCapital Group.

(3) Noble Affluent Limited is wholly-owned by Mr. Huang.

As at the Latest Practicable Date, none of the Shareholders who are required to abstain from voting in favour of the resolutions approving the Three-year RSU Grants have given the Company notice of their intention to vote against the resolutions at the EGM. When the Company subsequently becomes aware that such Shareholders may change their minds as to whether to abstain or vote against the resolution before the date of the EGM, the Company will immediately despatch a circular to the Shareholders or publish an announcement in accordance with Rule 2.07C of the Listing Rules notifying the Shareholders of the change and, if known, the reason for such change.

CLOSURE OF REGISTER OF MEMBERS

For determining the entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Friday, September 25, 2026 to Wednesday, September 30, 2026, both days inclusive, during which period, no share transfers will be registered and the record date will be on Wednesday, September 30, 2026. In order to qualify for attending and voting at the EGM, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong before 4:30 p.m. on Thursday, September 24, 2026.

EXTRAORDINARY GENERAL MEETING

Set out on pages 17 to 18 of this circular is the notice of the EGM at which, inter alia, ordinary resolutions will be proposed to the Independent Shareholders to consider and approve (i) the proposed grant of 208,617 RSUs to Mr. Feng; (ii) the proposed grant of 743,248 RSUs to Mr. Hu; and (iii) the proposed grant of 303,938 RSUs to Mr. Huang.

FORM OF PROXY

A form of proxy is enclosed for use at the EGM. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.angelalign.com). Whether or not you intend to attend the EGM, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding the EGM (i.e. before 9:00 a.m. on Monday, September 28, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the EGM or any adjournment thereof if they so wish. In such event, the form of proxy shall be deemed to be revoked.

VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules and Article 13.5 of the articles of association of the Company, at any general meeting a resolution put to the vote of the meeting is to be decided by way of a poll, except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Accordingly, the resolutions set out in the notice of EGM will be decided by way of a poll.

On a poll, every Shareholder present in person or by proxy or, in the case of a Shareholder being a corporation, by its duly authorised representative shall have one vote for every fully paid Share of which he is the holder. A Shareholder entitled to more than one vote needs not to use all his votes or cast all the votes he uses in the same way.

An announcement on the poll results will be published by the Company after the EGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATION

The Board (including all the independent non-executive Directors, but save and except the Selected Director Grantees) is of the view that the terms of the Three-year RSU Grants are fair and reasonable and the Three-year RSU Grants are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board (including all the independent non-executive Directors, but save and except the Selected Director Grantees) recommends the Shareholders to vote in favour of the ordinary resolutions in relation to (i) the proposed grant of 208,617 RSUs to Mr. Feng; (ii) the proposed grant of 743,248 RSUs to Mr. Hu; and (iii) the proposed grant of 303,938 RSUs to Mr. Huang to be proposed at the EGM.

Yours faithfully
By Order of the Board
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

ANGELALIGN TECHNOLOGY INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6699)

NOTICE IS HEREBY GIVEN THAT the extraordinary general meeting (the "**EGM**") of Angelalign Technology Inc. (時代天使科技有限公司) (the "**Company**") will be held at 6/F, Building No. 7, KIC Business Center, No. 500 Zhengli Road, Yangpu District, Shanghai, PRC on Wednesday, September 30, 2026 at 9:00 a.m. or at any adjournment thereof for the following purposes:

ORDINARY RESOLUTIONS

To consider and, if thought fit, pass, the following resolutions as ordinary resolutions:

1. the proposed grant of 208,617 RSUs to Mr. FENG Dai;

2. the proposed grant of 743,248 RSUs to Mr. HU Jiezhang;

3. the proposed grant of 303,938 RSUs to Mr. HUANG Kun; and

4. the Directors be and are hereby authorised, for and on behalf of the Company, to take all steps and do all acts and things as they consider to be necessary, appropriate or expedient in connection with and to implement or give effect to the Three-year RSU Grants, and to execute all such other documents, instruments and agreements deemed by them to be incidental to, ancillary to or in connection with the transactions herein.

By Order of the Board
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

Hong Kong, September 11, 2026

Notes:

1. Unless specifically indicated, details of the resolutions are set out in the circular of the Company dated September 11, 2026. Terms used therein shall have the same meanings as defined in the circular.

2. A shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend, speak and vote in his/her stead. The proxy does not need to be a shareholder of the Company.

3. To be valid, a form of proxy, together with the power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power of attorney or authority must be deposited with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but not less than 48 hours before the time appointed for holding the EGM (i.e. before 9:00 a.m. on Monday, September 28, 2026) or any adjournment thereof. Return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting if they so wish. In such event, the instrument appointing a proxy shall be deemed to be revoked.

4. All persons who are registered holders of shares of the Company at the close of business (Hong Kong time) on Wednesday, September 30, 2026 will be entitled to attend and vote at the meeting.

5. Where there are joint holders of any Shares, any one of such persons may vote at the EGM, either personally or by proxy, in respect of such Shares as if he were solely entitled thereto; but if more than one of such joint holders be present at the EGM personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such Shares will alone be entitled to vote in respect thereof.

6. The register of members of the Company will be closed from Friday, September 25, 2026 to Wednesday, September 30, 2026, both days inclusive, in order to determine the eligibility of shareholders to attend and vote at the EGM, during which period no share transfers will be registered. To be eligible to attend the EGM, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Thursday, September 24, 2026.

7. Pursuant to Rule 13.39(4) of the Listing Rules, the resolutions set out in this notice will be decided by poll at the EGM.

As at the date of this notice, the Board comprises Mr. FENG Dai, Mr. HU Jiezhang, Mr. HUANG Kun and Ms. DONG Li as executive Directors; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.